Alexandria Real Estate still faces severe headwinds as life science real estate demand remains weak and development oversupply persists. ARE's aggressive development pipeline and capital commitments have led to declining occupancy, a shrinking portfolio, and a nearly 30% projected FFO per share drop year-over-year. Management has slashed the dividend, cut development spending by 40% from post-pandemic peaks, and is selling noncore assets to stabilize leverage.